Description: Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Home Page: abliva.com
Medicon Village
Lund,
223 81
Sweden
Phone:
46 4 62 75 62 20
Officers
| Name | Title |
|---|---|
| Dr. Ellen K. Donnelly Ph.D. | Chief Exec. Officer |
| Ms. Catharina Jz Johansson | Deputy CEO, CFO & VP of Investor Relations |
| Dr. Eskil Elmér | Chief Scientific Officer & VP of Discovery |
| Daniel Schale | Director of Communications |
| Dr. Magnus Hansson | Chief Medical Officer and VP of Preclinical & Clinical Devel. |
| Dr. Lars Vedin | Consultant |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9725 |
| Price-to-Sales TTM: | 2680.8628 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |